CRVS

Corvus Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 7/10
  • Value↑ 6/10
Corvus Pharmaceuticals sales and earnings growth
CRVS Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 81.37%
  • FCF Y/Y↓ -29.71%
Corvus Pharmaceuticals gross and profit margin trends
CRVS Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -106.78%
Corvus Pharmaceuticals net debt vs free cash flow
CRVS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Corvus Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗